Ocular Therapeutix (OCUL) Total Current Liabilities (2013 - 2026)
Ocular Therapeutix's quarterly Total Current Liabilities came in at $47.7 million in Q1 2026, up 25.73% year-on-year from $37.9 million in Q1 2025, and down 6.15% quarter-over-quarter from $50.8 million in Q4 2025.
Ocular Therapeutix has reported Total Current Liabilities for 14 years, with the latest figure at $47.7 million in Q1 2026.
- For the quarter ending Q1 2026, Total Current Liabilities rose 25.73% year-over-year to $47.7 million; the trailing twelve-month figure through Mar 2026 stood at $47.7 million (up 25.73% YoY), and the FY2025 full-year result was $50.8 million, up 22.86% from the prior year.
- Total Current Liabilities for Q1 2026 stood at $47.7 million, down from $50.8 million in the prior quarter.
- The five-year high for Total Current Liabilities was $50.8 million in Q4 2025, with the low at $24.0 million in Q1 2022.
- Average Total Current Liabilities over 5 years is $35.5 million, with a median of $34.9 million recorded in 2023.
- Year-over-year, Total Current Liabilities decreased 18.23% in 2024 and surged 56.09% in 2025.
- Tracing OCUL's Total Current Liabilities over 5 years: stood at $31.4 million in 2022, then grew by 11.15% to $34.9 million in 2023, then advanced by 18.51% to $41.4 million in 2024, then increased by 22.86% to $50.8 million in 2025, then fell by 6.15% to $47.7 million in 2026.
- The last three Total Current Liabilities figures came in at $47.7 million (Q1 2026), $50.8 million (Q4 2025), and $49.3 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 16.35 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | 1.70 Mn |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 636.40 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | 66.94 Mn |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | 13.42 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 3.88 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 5.11 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 1.35 Bn |
| 10 | Ocular Therapeutix | 1.99 Bn | 1.99 Bn | 9.46 Mn | 47.68 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 47.68 Mn |
| Dec 31, 2025 | 50.81 Mn |
| Sep 30, 2025 | 49.29 Mn |
| Jun 30, 2025 | 42.93 Mn |
| Mar 31, 2025 | 37.93 Mn |
| Dec 31, 2024 | 41.35 Mn |
| Sep 30, 2024 | 36.36 Mn |
| Jun 30, 2024 | 29.97 Mn |
| Mar 31, 2024 | 24.30 Mn |
| Dec 31, 2023 | 34.90 Mn |
| Sep 30, 2023 | 35.07 Mn |
| Jun 30, 2023 | 32.36 Mn |
| Mar 31, 2023 | 29.72 Mn |
| Dec 31, 2022 | 31.40 Mn |
| Sep 30, 2022 | 29.27 Mn |
| Jun 30, 2022 | 26.11 Mn |
| Mar 31, 2022 | 23.96 Mn |
| Dec 31, 2021 | 26.34 Mn |
| Sep 30, 2021 | 25.16 Mn |
| Jun 30, 2021 | 21.55 Mn |
| Mar 31, 2021 | 27.44 Mn |
| Dec 31, 2020 | 26.66 Mn |
| Sep 30, 2020 | 22.91 Mn |
| Jun 30, 2020 | 13.80 Mn |
| Mar 31, 2020 | 11.11 Mn |
| Dec 31, 2019 | 12.03 Mn |
| Sep 30, 2019 | 11.01 Mn |
| Jun 30, 2019 | 10.13 Mn |
| Mar 31, 2019 | 8.61 Mn |
| Dec 31, 2018 | 9.16 Mn |
| Sep 30, 2018 | 13.41 Mn |
| Jun 30, 2018 | 11.90 Mn |
| Mar 31, 2018 | 13.15 Mn |
| Dec 31, 2017 | 13.43 Mn |
| Sep 30, 2017 | 10.95 Mn |
| Jun 30, 2017 | 13.13 Mn |
| Mar 31, 2017 | 8.66 Mn |
| Dec 31, 2016 | 8.30 Mn |
| Sep 30, 2016 | 8.24 Mn |
| Jun 30, 2016 | 6.42 Mn |
| Mar 31, 2016 | 6.00 Mn |
| Dec 31, 2015 | 5.38 Mn |
| Sep 30, 2015 | 11.18 Mn |
| Jun 30, 2015 | 9.59 Mn |
| Mar 31, 2015 | 7.23 Mn |
| Dec 31, 2014 | 5.87 Mn |
| Sep 30, 2014 | 3.38 Mn |
| Jun 30, 2014 | 4.49 Mn |
| Dec 31, 2013 | 3.34 Mn |